Edwards Lifesciences' impressive ROCE history and its ability to generate high returns on increasing amounts of capital employed indicate strong fundamentals. This warrants further research into the stock despite it being more 'expensive' than before.
Analysts reconfirmed revenue and earnings forecasts for Edwards Lifesciences, indicating no major change in business expectations following recent results. The price target increase suggests analysts believe the business's intrinsic value is improving.
Investors banking on Edwards Lifesciences' high P/E ratio might face a challenge as the firm's predicted market-aligned growth hints at a potential share price decline.
Pre-Market Stock Movers Gapping up $Align Technology(ALGN.US)$ (The orthodontics company surged 14% after posting adjusted earnings late Wednesday of $2.22 per share for the second quarter, beating estimates of $2.03 per share, according to Refinitiv. Revenue for the quarter also topped estimates, and revenue guidance for the year was above analyst expectations.) $Meta Platforms(META.US)$ (The Facebook parent jumped ne...